治疗念珠菌血症与侵袭性念珠菌感染新药rezafungin药理作用及临床评价研究进展

Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis

全球真菌感染日益严重,成为人类最难控制的疾病之一,造成巨大公共卫生负担。以念珠菌为主的真菌病原体可引起严重的侵入性和全身性疾病,甚至导致死亡。2023年3月22日,美国食品药品监督管理局(FDA)批准新型棘白菌素抗真菌药物rezafungin上市,用于治疗念珠菌血症与侵袭性念珠菌病,临床研究显示本品疗效较好且安全性高。本文就其药理作用、临床评价、安全性及用法用量等进行概述。

Rising global fungal infections represent a significant public health burden,which are among the most difficult diseases to manage in humans.Candida spp,a major aetiologic agent of fungal infections,can cause severe invasive and systemic diseases that can even be deadly.On March 22,2023,the FDA approved a novel echinocandin antifungal rezafungin to treat candidemia and invasive candidiasis.Clinical studies have shown that rezafungin has a good efficacy and safety for candidiasis infections.This review describes its pharmacological action,clinical evaluation,safety,usage and dosage.